Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21607023 | 0.86 | UGT2B7 (0.34) | IRAK4DYRK1ACLK1 | |
| SCHEMBL23479627 | 0.83 | — | — | |
| SCHEMBL827713 | 0.75 | CYP1A2 (0.44) | HDAC6IRAK4DYRK1AKDM4EMEN1 | |
| SCHEMBL31168473 | 0.75 | CYP1A2 (0.44) | HDAC6IRAK4DYRK1AKDM4EMEN1 | |
| SCHEMBL22778675 | 0.74 | HTR1B (0.39) | IRAK4KDM4E | |
| SCHEMBL12896074 | 0.74 | ALDH1A1 (0.35) | HDAC6DYRK1AKDM4EMEN1NPC1 | |
| SCHEMBL25918524 | 0.72 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL2609442 | 0.72 | DYRK1A (0.45) | DYRK1ACLK1KDM4EMEN1NPC1 | |
| SCHEMBL418936 | 0.71 | DYRK1A (0.33) | IRAK4DYRK1A | |
| SCHEMBL457106 | 0.71 | DYRK1A (0.38) | IRAK4DYRK1AALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180223045-A1 | POLYIMIDE PRECURSOR COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-01-04 | — | — | US | disclosed |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | HDAC6 562/4885IRAK4 1715/4885DYRK1A 4496/4885 |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HDAC6 1125/4885IRAK4 4256/4885DYRK1A 3476/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HDAC6 534/4885IRAK4 1827/4885DYRK1A 2576/4885 |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A3, SLC16A1, SLC16A7 | HDAC6 2301/4885IRAK4 495/4885DYRK1A 4285/4885 |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | HDAC6 137/4885IRAK4 618/4885DYRK1A 2818/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HDAC6 1125/4885IRAK4 4256/4885DYRK1A 3476/4885 |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | HDAC6 1341/4885IRAK4 2348/4885DYRK1A 1576/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HDAC6 534/4885IRAK4 1827/4885DYRK1A 2576/4885 |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | HDAC6 2245/4885IRAK4 301/4885DYRK1A 3970/4885 |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | ERBB2, EGFR, ERBB3 | HDAC6 832/4885IRAK4 3599/4885DYRK1A 43/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HDAC6 836/4885IRAK4 4591/4885DYRK1A 3517/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | HDAC6 1386/4885IRAK4 2080/4885DYRK1A 1389/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HDAC6 534/4885IRAK4 1827/4885DYRK1A 2576/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | HDAC6 892/4885IRAK4 4699/4885DYRK1A 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.